Evidence map›Paper›PMID 37298160›Full record

ArticleInternational journal of molecular sciences2023

Markers of NETosis in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome.

Tatiana Reshetnyak, Kamila Nurbaeva, Ivan Ptashnik, Anna Kudriaeva, Alexey Belogurov, Aleksandr Lila, Evgeny Nasonov

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. NETs: a new target for autoimmune disease.Frontiers in immunology · 2025
    Review
  10. Biomarkers for systemic lupus erythematosus: A scoping review.Immunity, inflammation and disease · 2024
    Article
  11. Article
  12. (Chemical) Roles of HOCl in Rheumatic Diseases.Antioxidants (Basel, Switzerland) · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Tatiana ReshetnyakV.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia.ORCID 0000-0003-3552-2522
Kamila NurbaevaV.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia.
Ivan PtashnikShemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.
Anna KudriaevaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.
Alexey BelogurovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia.
Aleksandr LilaV.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia.
Evgeny NasonovV.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia.
Russian Medical Academy of Continuous Professional Education · RUInstitute of Bioorganic Chemistry · RUAssociation of Rheumatologists of Russia · RUMoscow State University of Medicine and Dentistry · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutrophil Extracellular Traps (NETs) have been implicated in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) pathogenesis. The myeloperoxidase-deoxyribonucleic acid (MPO-DNA) complex and nucleosomes are serum markers of NETosis. The aim of this study was to assess these NETosis parameters as markers for SLE and APS diagnosis and their association with clinical features and disease activity. A total of 138 people were included in the cross-sectional study: 30 with SLE without APS, 47 with SLE and APS, 41 patients with primary antiphospholipid syndrome (PAPS), and 20 seemingly healthy individuals. Serum MPO-DNA complex and nucleosome levels were determined via an enzyme-linked immunosorbent assay (ELISA). Informed consent was obtained from all subjects involved in the study. The Ethics Committee of the V.A. Nasonova Research Institute of Rheumatology (Protocol No. 25 dated 23 December 2021) approved the study. In patients with SLE without APS, the levels of the MPO-DNA complex were significantly higher compared to patients with SLE with APS, with PAPS, and healthy controls (

Indexed as

Antiphospholipid SyndromeArthritisLupus Erythematosus, SystemicLupus NephritisBiomarkersCross-Sectional StudiesDNAHumansNucleosomesBiomarkersDNANucleosomesantiphospholipid antibodiesantiphospholipid syndromeMPO-DNA complexnephritisNETosisnucleosomessystemic lupus erythematosus

Identifiers

PMID37298160
PMCPMC10252548
OpenAlexW4378228088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.